Eli Lilly’s “triple g” drug helped patients lose about 28.7% of their body weight while also reducing pain associated with ...

Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: Knee Osteoarthritis Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering ...

SereNeuro Therapeutics revealed promising results for SN101, a first-in-class iPSC-derived therapy designed to treat chronic ...

Retatrutide treatment resulted in significant improvements in WOMAC pain scores and body weight compared with placebo in the TRIUMPH-4 trial.

In addition, the obesity drug also improved knee pain in participants, Eli Lilly noted. ・Seven additional Phase 3 trials for ...

Approved by the Drug Controller General of India (DCGI), the treatment offers to slow disease progression and promote cartilage maintenance for patients with Grade II and III knee OA ...

Professional organizations such as the American College of Rheumatology and the American Academy of Orthopaedic Surgeons ...

A new study led by investigators at Mass General Brigham finds that adding novel weight loss GLP-1 drugs semaglutide and tirzepatide to usual care represents a cost-effective treatment strategy for ...

Osteoarthritis, a condition that affects the joints, is growing increasingly common. Although exercise is a useful lifestyle intervention to ease pain, experts are unsure of the best type of exercise ...